Effectiveness of paroxetine in the treatment of obsessive–compulsive disorders

References

• Sadock BJ, Sadock VA. In: Kaplan & Sadock's Synopsis of Psychiatry 9th Edition. Lippincott Williams and Wilkins, USA(2003).
   Google Scholar
• Wagstaff AJ, Cheer SM, Matheson AJ et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs62(4), 655–703 (2002).
   PubMed Web of Science ®Google Scholar
• Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int. Clin. Psychopharmacol.14(Suppl. 2), S27–S33 (1999).
   Google Scholar
• Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs55(1), 85–120 (1998).
   PubMed Web of Science ®Google Scholar
• Golden RN, Nemeroff CB, McSorley O et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J. Clin. Psychiatry63(7) 577–584. (2002).
   PubMed Web of Science ®Google Scholar
• Bremner JD, Innis RB, Salpmen RM et al. Positronemission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch. Gen. Psychiatry54, 364–374 (1997).
   PubMed Web of Science ®Google Scholar
• Argyropoulos S, Hood SD, Adrover M et al. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol. Psych.56, 503–509 (2004).
   PubMed Web of Science ®Google Scholar
• Prakash A, Foster RH. Paroxetine: a review of its use in social anxiety disorder. CNS Drugs12, 151–169 (1999).
   Web of Science ®Google Scholar
• Pinna G, Costa E, Guidotti et al, Fluoxetine and norfluoxetine sterospecificall and selectively increase brain neurosteroid cintent at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl).24, 1–11 (2006).
   Google Scholar
• Uzunova V, Sheline Y, Davis JM et al. A increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl Acad. Sci. USA95, 3239–3244. (1998).
   PubMed Web of Science ®Google Scholar
• Brambilla F, Mellado C, Alciati A et al. Plasma concentration of anxiolytic neuroactive steroids in men with panic disoirder Psychiatry Res.135, 185–190, (2005).
   PubMed Web of Science ®Google Scholar
• Owens MJ, Knight DL. Human monoamine transporter binding profile of the SSRIs. American Psychiatric Association 2000 Annual Meeting: The Doctor–Patient Relationship: New Research Abstracts. Chicago, USA, May 13, 144–145 (2000).
   Google Scholar
• Thomas DR, Nelson DR , Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl).93(2), 193–200 (1987).
   PubMed Web of Science ®Google Scholar
• Kaye CM, Haddock RE, Langley PF et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta. Psychiatr. Scand.80(Suppl. 350), 60–75 (1989).
   PubMedGoogle Scholar
• Greb WH, Brett MA, Buscher G et al. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta. Psychiatr. Scand.80(Suppl. 350), 99–101 (1988).
   Web of Science ®Google Scholar
• Physicians Desk Reference for Paxil.
   Google Scholar
• Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics5, 335–346 (1995).
   PubMedGoogle Scholar
• Bayer AJ, Roberts NA, Allen EA et al. The pharmacokinetics of paroxetine in the elderly. Acta. Psychiatr. Scand.80(Suppl. 350), 85–86 (1988).
   Web of Science ®Google Scholar
• Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs41(2), 225–253 (1991).
   PubMed Web of Science ®Google Scholar
• Doyle GD, Laher M, Kelly JG et al. The pharmacokinetics of paroxetine in renal impairment. Acta. Psychiatr. Scand.80(Suppl. 350), 89–90 (1989).
   Web of Science ®Google Scholar
• Krastev Z,Terziivanov D, Vlahov V et al. The pharmacokinetics of paroxetine inpatients with liver cirrhosist. Acta. Psychiatr. Scand.80(Suppl. 350), 91–92 (1989).
   Web of Science ®Google Scholar
• Hollander E, Allen A, Steiner M et al. Acute and long-term treatment and prevention of relapse of obsessive–compulsive disorder with paroxetine. J. Clin. Psychiatry64, 1113–1121 (2003).
   PubMed Web of Science ®Google Scholar
• Wheadon DE, Bushnell WD, Steiner MA. A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive–compulsive disorder. In: Abstracts of Panels and Posters presented at the Annual Meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico (1993).
   Google Scholar
• Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive–compulsive disorder. Br. J. Psychiatry169, 468–474 (1996).
   PubMed Web of Science ®Google Scholar
• Kamijima K, Murasaki M, Asai M et al. Paroxetine in the treatment of obsessive–compulsive disorder: randomized, double-blind, placebo-controlledstudy. Psy. Clin. Neuroscience.58, 427–433 (2004).
   PubMed Web of Science ®Google Scholar
• Baxter LR, Phelps ME, Mazziotta JC et al. Local cerebral glucose metabolic rates in obsessive–compulsive disorder – a comparison with rates in unipolar depression and in normal controls. Arch. Gen. Psychiatry44, 211–218 (1987).
   PubMed Web of Science ®Google Scholar
• Hansen ES, Hasselbalch S, Law I et al. The caudate nucleus in obsessive–compulsive disorder reduced metabolism following treatment with paroxetine: a PET study. Int. J. Neuropsychopharmacol.5, 1–10 (2002).
   PubMed Web of Science ®Google Scholar
• Denys D, van der Wee N, van Megen HJ et al. A double blind comparison of venlafaxine and paroxetine in obsessive–compulsive disorder. J. Clin. Psychopharmacol.23, 568–575 (2003).
   PubMed Web of Science ®Google Scholar
• Denys D, van Megen HJ, van der Wee N et al. A double-blind switch study of paroxetine and venlafaxine in obsessive–compulsive disorder. J. Clin. Psychiatry65, 37–43 (2004).
   PubMed Web of Science ®Google Scholar
• Hollander E, Wong CM. Obsessive–compulsive spectrum disorders. J. Clin. Psychiatry56(Suppl. 4), 3–6 (1995).
   PubMed Web of Science ®Google Scholar
• Marazziti D, Dell'Osso L, Presta S et al. Platelet [3H]paroxetine binding in patients with OCD-related disorders. Psychiatry Res.89(3), 223–238 (1999).
   PubMed Web of Science ®Google Scholar
• Bruun RD, Budman CL. Paroxetine treatment of episodic rages associated with Tourette''s disorder. J. Clin. Psychiatry59, 581–584 (1998).
   PubMed Web of Science ®Google Scholar
• Oosterbaan DB, van Balkom AJ, van Boeijen CA. An open study of paroxetine in hypochondriasis. Prog. Neuropsychopharmacol. Biol. Psychiatry25, 1023–1033 (2001).
   PubMed Web of Science ®Google Scholar
• Kim SW, Grant JE, Adson DE. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling.J. Clin. Psychiatry63, 501–507 (2002).
   PubMed Web of Science ®Google Scholar
• Kamijima K, Maeda H, Kawai M et al. Post-marketing surveillance for paroxetine hydrochloride hydrate (Paxil Tablet) – Interim report of drug use investigation. Jpn. Pharmacol. Ther.31, 745–765 (2003).
   Google Scholar
• Montgomery S, Zohar J. In: Obsessive–Compulsive Disorder. Martin Dunitz (Ed.), London, UK (1999).
   Google Scholar
• Montgomery SA. Treatment of obsessive–compulsive disorder. CNS Spectrum5(Suppl. 3), 46–50 (1999).
   Google Scholar
• Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive–compulsive disorder. Psychiatr. Serv.54, 1111–1118 (2003).
   PubMed Web of Science ®Google Scholar
• Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive compulsive disorder. J. Clin. Psychiatry53(Suppl.), 29–37 (1992).
   PubMed Web of Science ®Google Scholar
• Owashi T, Kamijima K. Kyohakusei shogai (Obsessive–compulsive disorder). Rinsho To Kenkyu.78, 1797–1803 (2001).
   Google Scholar
• D'Amico G, Cedro C, Muscatello MR et al. Olanzapine augmentation of paroxetine-refractory obsessive–compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry27, 619–623 (2003).
   PubMed Web of Science ®Google Scholar
• Rasmussen SA, Eisen JL.The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr. Clin. North Am.15, 743–758 (1992).
   PubMed Web of Science ®Google Scholar
• Laired LK. Issues in the monopharmacotherapy and polypharmacotherapy of obsessive–compulsive disorder. Psychopharmacol. Bull.32(4), 569–578 (1996).
   PubMedGoogle Scholar
• Weissman MM, Bland RC, Canino GJ et al. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group.J. Clin. Psychiatry55(Suppl.), 5–10 (1994).
   PubMed Web of Science ®Google Scholar
• Saxena S, Brody AL, Ho ML et al. Differential brain metabolic predictors of response to paroxetine in obsessive–compulsive disorder versus major depression. Am. J. Psychiatry160, 522–532 (2003).
   PubMed Web of Science ®Google Scholar
• Hwang MY, Morgan JE, Losconzcy MF. Clinical and neuropsychological profiles of obsessive–compulsive schizophrenia: a pilot study. J. Neuropsych. Clin. Neurosci.12, 91–94 (2000).
   PubMed Web of Science ®Google Scholar
• Tibbo P, Warneke L. Obsessive–compulsive disorder in schizophrenia: epidemiologic and biologic overlap. J. Psych. Neurosci.24, 15–24 (1999).
   PubMed Web of Science ®Google Scholar
• Levkovitch Y, Kronnenberg Y, Gaoni B. Can clozapine trigger OCD? J. Am. Acad. Child Adolesc. Psych.34, 263 (1995).
   PubMed Web of Science ®Google Scholar
• Strous RD, Patel JK, Zimmet S et al. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features. Am. J. Psychiatry156, 973–974 (1999).
   PubMed Web of Science ®Google Scholar
• Thoren P, Asberg M, Cronholm B et al. Clomipramine treatment of obsessive–compulsive disorder. I. A controlled clinical trial. Arch. Gen. Psychiatry.37, 1281–1285 (1980).
   PubMed Web of Science ®Google Scholar
• Zohar J, Zohar-Kadouch R, Kindler S. Current concepts in the pharmacological treatment of obsessive–compulsive disorder. Drugs42, 218 (1992).
   Google Scholar
• Thoren P, Asberg M, Bertilsson L et al. Clomipramine treatment of obsessive–compulsive disorder. II Biochemical aspects. Arch. Gen. Psychiatry.37, 1289–1294 (1980).
   PubMed Web of Science ®Google Scholar
• Denys D, Zohar J, German GM et al. The role of dopamine in obsessive–compulsive disorder: preclinical and clinical evidence. J. Clin. Psychiatry65(Suppl. 14), 11–17 (2004).
   PubMed Web of Science ®Google Scholar
• McDougle CJ. Update on pharmacologic management of OCD: agent and augmentation.J. Clin. Psychiatry58(Suppl. 12), 11–17 (1997).
   PubMedGoogle Scholar
• Benel D, Greenberg BD, Cora-Locatelli G et al. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive–compulsive disorder. Mol. Psychiatry4, 463–466 (1999).
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Price LH et al. Evidence for linkage disequilibrium between serotonin transporter protein gene(SCL6A4) and obsessive–compulsive disorder. Mol. Psychiatry3, 270–273 (1998).
   PubMed Web of Science ®Google Scholar
• Kayayiorgou M, Altemus M, Galke BL et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive–compulsive disorder. Proc. Natl Acad. Sci. USA94, 4572–4575 (1997).
   PubMed Web of Science ®Google Scholar
• Kayayiorgou M, Sobin C, Blundell ML et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibity to obsessive–compulsive disorder. Biol. Psychiatry45, 1178–1189 (1999).
   PubMed Web of Science ®Google Scholar
• Ohara K, Nagai M, Suzuki Y et al. No association between anxiety disorders and catechol-O-methyltransferase polymorphism. Psychiatry Res.80, 145–148 (1998).
   PubMed Web of Science ®Google Scholar
• Billett EA, Richter MA, Sam F et al. Investigation of dopamine system genes in obsessive–compulsive disorder. Psychiatr. Genet.8, 163–169 (1998).
   PubMed Web of Science ®Google Scholar
• Frisch A, Michaelovsky E, Rockah R et al. Association between obsessive–compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur. Neuropsychopharmacol.10, 205–209 (2000).
   PubMed Web of Science ®Google Scholar
• Hollander E, Stein DJ, Broatch J et al.A pharmacoeconomic and quality of life study of obsessive–compulsive disorder. CNS Spectrum2, 16–25 (1997).
   Google Scholar
• Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive– compulsive disorder.J. Clin. Psychiatry55(Suppl.), 5–10 (1994).
   PubMed Web of Science ®Google Scholar
• Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J. Clin. Psychiatry65, 1696–707 (2004).
   PubMed Web of Science ®Google Scholar
• Lydiard RB, Brawman-Mintzer O. Anxious depression. J. Clin. Psychiatry59(Suppl. 18), 10–17 (1998).
   PubMed Web of Science ®Google Scholar